Get started
Work

Long-Term Outcomes of 133 Patients with Intermediate-Risk Acute Myeloid Leukemia Treated with High-Dose Chemotherapy and Autologous Stem Cell Rescue in First Complete Remission

Year: 2015
Type: article
Study design: Observational Study
Abstract: In 2014, high-dose chemotherapy with autologous stem cell rescue (autoSCT) was removed from the NCCN guidelines as a recommended treatment for patients <60 years old with intermediate-risk (int-risk) AML in first complete remission (CR1). We comprehensively reviewed the long-term outcomes of all patients with int-risk AML treated with autoSCT in CR1 at our institution.
DOI: 10.1016/j.bbmt.2014.11.197
Authors: Gabriel N. Mannis, Thomas G. Martin, Lloyd E. Damon, Aaron C. Logan, Weiyun Ai, Karin M.L. Gaensler, Lawrence D. Kaplan, Anuj Mahindra, Rebecca L. Olin, Peter Sayre, Catherine C. Smith, Jeffrey L. Wolf, Jimmy Hwang, Charalambos Andreadis
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2152431808
FWCI: 0.227
Cites:
Cited by: 1
Related to: 10